专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2018005769A1 COMPOSITIONS AND METHODS FOR ACTIVATING ANTIGEN PRESENTING CELLS WITH CHIMERIC POLIOVIRUS 审中-公开
标题翻译：用嵌合脊髓灰质炎病毒活化抗原呈递细胞的组合物和方法
公开(公告)号：WO2018005769A1
公开(公告)日：2018-01-04
申请号：PCT/US2017/039953
申请日：2017-06-29
申请人： DUKE UNIVERSITY
发明人： NAIR, Smita , BROWN, Michael , BIGNER, Darell , GROMEIER, Mathias
IPC分类号： A01N63/00 , A61K31/739 , A61K35/14
摘要： Chimeric poliovirus is capable of activating antigen presenting cells. The activation of the antigen presenting cells may be in vitro, ex vivo, or in vivo. The activated antigen presenting cells may be administered alone or with an antigen or vaccine. The activated antigen may be loaded in vitro or ex vivo with antigen to form antigen-loaded, activated, antigen presenting cells. These may be administered therapeutically. Therapeutic administration of antigen presenting cells may be used as an adjuvant to other therapies.
摘要翻译：嵌合脊髓灰质炎病毒能够激活抗原呈递细胞。抗原呈递细胞的活化可以是体外，离体或体内的。激活的抗原呈递细胞可以单独施用或与抗原或疫苗一起施用。活化的抗原可以在体外或体外用抗原加载以形成抗原加载的，活化的抗原呈递细胞。这些可以在治疗上施用。抗原呈递细胞的治疗性施用可以用作其他疗法的佐剂。

2. 发明申请

WO2017079520A1 COMBINATION THERAPY OF IMMUNOTOXIN AND CHECKPOINT INHIBITOR 审中-公开
标题翻译：免疫毒素与检查点抑制剂的联合治疗
公开(公告)号：WO2017079520A1
公开(公告)日：2017-05-11
申请号：PCT/US2016/060469
申请日：2016-11-04
申请人： DUKE UNIVERSITY , THE GOVERNMENT OF THE UNITED STATES AS REPRESENTED BY THE SECRETARY OF HEALTH AND HUMAN SERVICES, NATIONAL INSTITUTES OF HEALTH
发明人： BIGNER, Darell , VIDYALAKSHMI, Chandramohan , NAIR, Smita , GROMEIER, Matthias , BAO, Xuhui , PASTAN, Ira H.
IPC分类号： A61K39/395 , A61K47/48
CPC分类号： A61K39/395 , A61K31/00 , A61K39/3955 , A61K2039/505 , A61K2039/507 , C07K16/2818 , C07K16/2863 , C07K16/30 , C07K2317/624 , C07K2317/73 , C07K2317/76 , C07K2319/55 , A61K2300/00
摘要： Regional, tumor-targeted, cytotoxic therapy, such as D2C7-immunotoxin (D2C7-IT), not only specifically target and destroy tumor cells, but in the process initiate immune events that promote an in situ vaccine effect. The antitumor effects are amplified by immune checkpoint blockade which engenders a long-term systemic immune response that effectively eliminates all tumor cells.
摘要翻译： D2C7-免疫毒素（D2C7-IT）等区域性，肿瘤靶向的细胞毒性疗法不仅特异性靶向并破坏肿瘤细胞，而且在该过程中启动促进原位疫苗的免疫事件影响。抗肿瘤效应通过免疫检查点阻断来扩增，其产生长期全身性免疫应答，其有效地消除所有肿瘤细胞。

3. 发明申请

WO2017011440A1 DETECTION OF TUMOR-DERIVED DNA IN CEREBROSPINAL FLUID 审中-公开
标题翻译：检测肿瘤衍生的DNA在脑脊液中
公开(公告)号：WO2017011440A1
公开(公告)日：2017-01-19
申请号：PCT/US2016/041862
申请日：2016-07-12
申请人： THE JOHNS HOPKINS UNIVERSITY
发明人： BETTEGOWDA, Chetan , KINZLER, Kenneth W. , VOGELSTEIN, Bert , WANG, Yuxuan , DIAZ, Luis , PAPADOPOULOS, Nickolas
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6886 , C12Q2600/156
摘要： As cell-free DNA from brain and spinal cord tumors cannot usually be detected in the blood, we assessed the cerebrospinal fluid (CSF) that bathes the CNS for tumor DNA, here termed CSF-tDNA. The results suggest that CSF-tDNA could be useful for the management of patients with primary tumors of the brain or spinal cord.
摘要翻译：由于通常不能在血液中检测到来自脑和脊髓肿瘤的无细胞DNA，因此我们评估了将CNS用于肿瘤DNA的脑脊液（CSF），这里称为CSF-tDNA。结果表明CSF-tDNA可用于治疗脑或脊髓原发性肿瘤患者。

4. 发明申请

WO2016134136A2 GENOMIC ALTERATIONS IN THE TUMOR AND CIRCULATION OF PANCREATIC CANCER PATIENTS 审中-公开
标题翻译：胰腺癌患者肿瘤和循环中的基因变异
公开(公告)号：WO2016134136A2
公开(公告)日：2016-08-25
申请号：PCT/US2016/018450
申请日：2016-02-18
申请人： THE JOHNS HOPKINS UNIVERSITY
发明人： VELCULESCU, Victor , SAUSEN, Mark , ADLEFF, Vilmos , PHALLEN, Jillian
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6827 , C12Q1/6816 , C12Q1/6886 , C12Q2600/106 , C12Q2600/112 , C12Q2600/118 , C12Q2600/156
摘要： Pancreatic adenocarcinoma has the worst overall mortality of any solid tumor, with only 7% of patients surviving after 5 years. To evaluate the clinical implications of genomic alterations in this low cellularity tumor type, we deeply sequenced the genomes of 101 enriched pancreatic adenocarcinomas from patients who underwent potentially curative resections and used non-invasive approaches to examine tumor specific mutations in the circulation of these patients. These analyses revealed somatic mutations in chromatin regulating genes including MLL and ARID1A in 20% of patients that were associated with improved survival. Liquid biopsy analyses of cell free plasma DNA revealed that 43% of patients with localized disease had detectable circulating tumor DNA (ctDNA) in their blood at the time of diagnosis. Detection of ctDNA after resection predicted clinical relapse and poor outcome, and disease recurrence by ctDNA was detected 6.5 months earlier than with standard CT imaging.
摘要翻译：胰腺癌具有任何实体瘤的总死亡率最差，5年后只有7％的患者存活。为了评估基因组改变在这种低细胞性肿瘤类型中的临床意义，我们对经历了潜在治愈性切除术的患者进行了101个富集的胰腺腺癌的基因组测序，并使用非侵入性方法来检查这些患者的循环中的肿瘤特异性突变。这些分析揭示了染色质调节基因中的体细胞突变，包括MLL和ARID1A在20％与改善生存相关的患者中。无细胞血浆DNA的液体活检分析显示，43％的局部疾病患者在诊断时血液中可检测到循环肿瘤DNA（ctDNA）。检测切除后的ctDNA预测临床复发和结果不良，ctDNA的疾病复发比标准CT成像早6.5个月。

5. 发明申请

WO2015085099A1 AUTOIMMUNE ANTIGENS AND CANCER 审中-公开
标题翻译：自动免疫抗体和癌症
公开(公告)号：WO2015085099A1
公开(公告)日：2015-06-11
申请号：PCT/US2014/068635
申请日：2014-12-04
申请人： THE JOHNS HOPKINS UNIVERSITY
发明人： DARRAH, Erika , SHAH, Ami A. , CASCIOLA-ROSEN, Livia A. , ROSEN, Anthony , JOSEPH, Christine , VOGELSTEIN, Bert , KINZLER, Kenneth W. , PAPADOPOULOS, Nickolas
IPC分类号： A61K38/16 , A61K38/17 , A61P35/00
CPC分类号： A61K39/0008 , A61K38/00 , A61K2039/585
摘要： Autoimmune diseases are thought to be initiated by exposures to foreign antigens that cross-react with endogenous molecules. Analyses of peripheral blood lymphocytes and serum suggested that mutations in autoimmune antigen targets sparked cellular immunity and cross-reactive humoral immune responses. Acquired immunity to autoimmune antigens can help control naturally occurring cancers.
摘要翻译：自身免疫性疾病被认为是通过暴露于与内源性分子交叉反应的外来抗原来引发的。外周血淋巴细胞和血清的分析表明，自身免疫抗原靶突变引发细胞免疫和交叉反应性体液免疫应答。对自身免疫性抗原的获得性免疫可以帮助控制天然存在的癌症。

6. 发明申请

WO2013003583A2 SOMATIC MUTATIONS IN ATRX IN BRAIN CANCER 审中-公开
标题翻译：脑癌中ATRX中的SOMATIC MUTATIONS
公开(公告)号：WO2013003583A2
公开(公告)日：2013-01-03
申请号：PCT/US2012/044631
申请日：2012-06-28
申请人： DUKE UNIVERSITY , THE JOHNS HOPKINS UNIVERSITY , YAN, Hai , BIGNER, Darell , VOGELSTEIN, Bert , KINZLER, Kenneth W. , MEEKER, Alan , HRUBAN, Ralph , PAPADAPOULOS, Nickolas , DIAZ, Luis , JIAO, Yuchen
发明人： YAN, Hai , BIGNER, Darell , VOGELSTEIN, Bert , KINZLER, Kenneth W. , MEEKER, Alan , HRUBAN, Ralph , PAPADAPOULOS, Nickolas , DIAZ, Luis , JIAO, Yuchen
CPC分类号： C12Q1/6886 , C07K16/40 , C12N15/1137 , C12Q2600/118 , C12Q2600/156 , G01N33/57407
摘要： We determined the sequence of ATRX and DAXX in 447 cancers from various sites. We found mutations most commonly in pediatric glioblastoma multiformae (GBM) (11.1%), adult GBM (6.5%), oligodendrogliomas (7.7%) and medulloblastomas (1.5%); and showed that Alternative Lengthening of Telomeres (ALT), a telomerase-independent telomere maintenance mechanism found in cancers that have not activated telomerase, perfectly correlated with somatic mutations of either gene. In contrast, neuroblastomas, and adenocarcinomas of the ovary, breast, and pancreas were negative for mutations in ATRX and DAXX. Alterations in ATRX or DAXX define a specific molecular pathway that is closely associated with an alternative telomere maintenance function in human cancers.
摘要翻译：我们确定了来自各个位点的447例癌症中ATRX和DAXX的序列。我们发现多形性小儿多形性成胶质细胞瘤（GBM）（11.1％），成人GBM（6.5％），少突胶质细胞瘤（7.7％）和成神经管细胞瘤（1.5％）中最常见的突变; 并且表明，在未激活端粒酶的癌症中发现端粒酶非依赖端粒维持机制的替代延长端粒（ALT）与任一基因的体细胞突变完全相关。相比之下，成骨细胞瘤和卵巢，乳腺和胰腺腺癌对于ATRX和DAXX中的突变是阴性的。 ATRX或DAXX中的改变定义了与人类癌症中替代端粒维持功能密切相关的特定分子途径。

7. 发明申请

WO2012178034A3 MUTATIONS IN PANCREATIC NEOPLASMS 审中-公开
公开(公告)号：WO2012178034A3
公开(公告)日：2012-12-27
申请号：PCT/US2012/043783
申请日：2012-06-22
申请人： THE JOHNS HOPKINS UNIVERSITY , VOGELSTEIN, Bert , KINZLER, Kenneth W. , WU, Jian , DIAZ, Luis , PAPADOPOULOS, Nickolas , MATTHAEI, Hanno , HRUBAN, Ralph , MAITRA, Anirban
发明人： VOGELSTEIN, Bert , KINZLER, Kenneth W. , WU, Jian , DIAZ, Luis , PAPADOPOULOS, Nickolas , MATTHAEI, Hanno , HRUBAN, Ralph , MAITRA, Anirban
IPC分类号： C12Q1/68 , C12N15/11
摘要： To help reveal the pathogenesis of these lesions, we purified the DNA from Intraductal Papillary Mucinous Neoplasm (IPMN) cyst fluids from 19 patients and searched for mutations in 169 genes commonly altered in human cancers. We identified recurrent mutations at codon 201 of GNAS. We found that GNAS mutations were present in 66% of IPMNs and that either KRAS or GNAS mutations could be identified in 96%. In eight cases, we could investigate invasive adenocarcinomas that developed in association with IPMNs containing GNAS mutations. In seven of these eight cases, the GNAS mutations present in the IPMNs were also found in the invasive lesion. GNAS mutations were not found in other types of cystic neoplasms of the pancreas or in invasive adenocarcinomas not associated with IPMNs. These data suggest that GNAS mutations can inform the diagnosis and management of patients with cystic pancreatic lesions.

8. 发明申请

WO2012099881A3 MUTANT PROTEINS AS CANCER-SPECIFIC BIOMARKERS 审中-公开
公开(公告)号：WO2012099881A3
公开(公告)日：2012-07-26
申请号：PCT/US2012/021553
申请日：2012-01-17
申请人： THE JOHN HOPKINS UNIVERSITY , VOGELSTEIN, Bert , WANG, Qing , PANDEY, Akhilesh , KINZLER, Kenneth W. , PAPADOPOULOS, Nickolas
发明人： VOGELSTEIN, Bert , WANG, Qing , PANDEY, Akhilesh , KINZLER, Kenneth W. , PAPADOPOULOS, Nickolas
IPC分类号： G01N33/68 , G01N33/551 , G01N33/574
摘要： Altered protein products resulting from somatic mutations are directly identified and quantified by mass spectrometry. The peptides expressed from normal and mutant alleles are detected by Selected Reaction Monitoring (SRM) of their product ions using a triple quadrupole mass spectrometer. As a prototypical example of this approach, we quantify the number and fraction of mutant Ras protein present in cancer cell lines. There were an average of 1.3 million molecules of Ras protein per cell and the ratio of mutant to normal Ras proteins ranged from 0.49 to 5.6. Similarly, we detected and quantified mutant Ras proteins in clinical specimens such as colorectal and pancreatic tumor tissues as well as in pre-malignant pancreatic cyst fluids. These methods are useful for diagnostic applications.

9. 发明申请

WO2012075490A3 ANTI-PODOPLANIN ANTIBODIES AND METHODS OF USE 审中-公开
公开(公告)号：WO2012075490A3
公开(公告)日：2012-06-07
申请号：PCT/US2011/063284
申请日：2011-12-05
申请人： DUKE UNIVERSITY , THE GOVERNMENT OF THE UNITED STATES, AS REPRESENTED BY, THE SECRETARY OF HEALTH AND HUMAN SERVICES, NATIONAL INSTITUTE OF HEALTH , BIGNER, Darell , KUAN, Chien-Tsun , PASTAN, Ira H. , CHANDRAMOHAN, Vidyalakshmi
发明人： BIGNER, Darell , KUAN, Chien-Tsun , PASTAN, Ira H. , CHANDRAMOHAN, Vidyalakshmi
IPC分类号： A61K39/395 , A61K38/16 , A61K48/00 , A61P37/00
摘要： Recombinant scFv-immunotoxins target tumor cells expressing human podoplanin but not podoplanin-negative or normal cells. The immunotoxins can be used for treatment of malignant glioma patients or any malignant tumor expressing podoplanin. One such immunotoxin comprises a modified Pseudomonas exotoxin (PE38) attached to the scFv antibody fragment. This immunotoxin can be used as a therapeutic drug for the treatment of malignant gliomas and other cancers.

10. 发明申请

WO2012071216A3 ANTIBODIES FOR TUMOR GANGLIOSIDES 审中-公开
公开(公告)号：WO2012071216A3
公开(公告)日：2012-05-31
申请号：PCT/US2011/060759
申请日：2011-11-15
申请人： DUKE UNIVERSITY , THE GOVERNMENT OF THE UNITED STATES, AS REPRESENTED BY, THE SECRETARY OF HEALTH AND HUMAN SERVICES, NATIONAL INSTITUTE OF HEALTH , BIGNER, Darell , KUAN, Chien-Tsun , PASTAN, Ira H. , PIAO, Hailan
发明人： BIGNER, Darell , KUAN, Chien-Tsun , PASTAN, Ira H. , PIAO, Hailan
IPC分类号： C07K16/30 , C12N15/13 , G01N33/574 , A61K39/395 , A61P35/00
摘要： High affinity antibodies were made to gangliosides expressed on tumor cells. The antibodies can be used analytically, diagnostically, therapeutically, and theranostically. The antibodies may be used to target cytotoxic reagents to tumor cells, thus minimizing full-body toxicity. The antibodies may also be used with out added cytotoxin. The antibodies may be detectably labeled or labelable for analytic and diagnostic purposes. The combination of specificity and affinity of the antibodies render them particularly useful.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式